



Preparation of phosphopeptide thioesters by Fmoc- and Fmoc(2-F)-solid phase synthesis

Koki Hasegawa, Yin Lin Sha, Jeong Kyu Bang, Toru Kawakami, Kenichi Akaji & Saburo Aimoto*

Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan

(* Author for correspondence, e-mail: aimoto@protein.osaka-u.ac.jp, phone: +81-6-6879-8601, fax: +81-6-6879-8603)

Received 7 January 2002; Accepted 13 March 2002

Key words: Fmoc chemistry, Fmoc(2-F), peptide thioester, phosphopeptide, reagent A, thioester method

Summary

Efficient methods for the preparation of phosphopeptide thioesters were examined, using Fmoc-based solid-phase method. Phosphopeptide thioesters were obtained in good yields by the use of 1-methylpyrrolidine, hexamethylenimine and 1-hydroxybenzotriazole in a DMSO-DMF (1:1, v/v) solution for deblocking the Fmoc groups. Epimerization, which is often observed at the C-terminal amino acid, was effectively suppressed by shortening the time of deblocking process via the use of highly base sensitive Fmoc(2-F) groups for α -amino protection.

Abbreviations: Alko resin (Wang resin), 4-hydroxymethylphenoxyethylated copoly(styrene-1% divinylbenzene) resin; Boc, *t*-butoxycarbonyl; Bu^t, *t*-butyl; cPen, cyclopentyl; DCC, dicyclohexylcarbodiimide; DCM, dichloromethane; DIEA, *N,N*-diisopropylethylamine; DMSO, dimethyl sulfoxide; DMF, *N,N*-dimethylformamide; DTT, dithiothreitol; EDT, 1,2-ethanedithiol; Fmoc, 9-fluorenylmethoxycarbonyl; Fmoc(2-F), 9-(2-fluoro)fluorenylmethoxycarbonyl; GC, gas chromatography; HBTU, *O*-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; HOCH₂-Pam, 4-(hydroxymethyl)phenylacetamidomethyl; HOOBt, 3,4-dihydroxy-4-oxo-1,2,3-benzotriazine; MALDI-TOF, matrix assisted laser desorption ionization time-of-flight; NMP, 1-methylpyrrolidin-2-one; NMR, nuclear magnetic resonance; NH₂-SAL, 4-(α -amino-2,4-dimethoxybenzyl)phenoxyethyl; MBHA, 4-methylbenzhydrylamine; RP-HPLC, reversed-phase high performance liquid chromatography; TFA, trifluoroacetic acid; TFMSA, trifluoromethanesulfonic acid; THF, tetrahydrofuran; Trt, triphenylmethyl; Tos, *p*-toluenesulfonyl; v/v, volume ratio; wt/v, weight by volume ratio.

Introduction

In 1991, Hojo and Aimoto reported on a method for polypeptide synthesis, which employed *S*-alkyl peptide thioesters (peptide thioesters) as building blocks [1]. Since then, improvements have been made to the thioester method, and it has been applied to the synthesis of a variety of polypeptides, including phosphopeptides [2–6]. Peptide thioesters are currently in use as intermediates not only in the thioester method, but also in the native chemical ligation method as well as related reactions used in polypeptide synthesis [7,

8]. However, a very basic problem that still remains to be solved involves the difficulty in the preparation of peptide thioesters. In particular, the synthetic yields of phosphopeptide thioesters are frequently low when they are prepared by a Boc solid-phase method using an MBHA resin [6]. Furthermore, as phosphorylated amino acid residues are often located in acid regions in proteins, there is the additional problem of aspartyl residue conversion to succinimide derivatives during peptide assembly [9, 10].

We wish to report herein on an improved method for the synthesis of a phosphopeptide thioester

based on Fmoc chemistry, adopting the thioester of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13), Met-Ser(PO₃H₂)-Asp-Asn-Asp-Asp-Ile-Glu-Val-Glu-Ser(PO₃H₂)-Asp-Ala-SC(CH₃)₂CH₂CO-Leu, as a model compound.

Material and method

Fmoc-amino acid derivatives were purchased from the Peptide Institute Inc. (Osaka, Japan). Fmoc-Ser[PO(OBzl)OH]-OH was purchased from Novabiochem (Läufelfingen, Switzerland). Fmoc-Leu Alko resin, NMP, DIEA, and TFA were purchased from Watanabe Chemical Ind. Ltd. (Hiroshima, Japan). 1-Methylpyrrolidine, hexamethylenimine and 2-fluorofluorene were purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan). The amino acid derivatives used in the solid phase peptide syntheses were of the L-configuration except for glycine. Reversed-phase HPLC (RP-HPLC) was performed using a linear increasing gradient of acetonitrile in 0.1% aqueous TFA. Amino acid compositions of peptides were analyzed on an L-8500 amino acid analyzer (Hitachi Ltd., Tokyo) after hydrolysis with constant boiling point HCl (Nacalai Tesque, Kyoto, Japan) at 110 °C for 24 h in an evacuated sealed tube. Analyses of resin-bound amino acids were carried out after hydrolysis with a reagent containing 12 M HCl (50 μL) and propionic acid (50 μL) at 110 °C for 24 h in an evacuated sealed tube. All yields were calculated based on data obtained by amino acid analyses. Peptide molecular masses were determined by MALDI-TOF mass spectrometry using a VoyagerTM DE (PerSeptive Biosystems Inc., Framingham, MA). The matrices used were α-cyano-4-hydroxycinnamic acid or sinapinic acid. The composition of the D-Ala isomer was determined by using a G-3500 gas chromatograph (GC) (Hitachi Ltd., Tokyo) equipped an L-Val coated capillary, CHROMPACKTM column (GL Sciences Inc., Netherlands).

Preparation of

Fmoc-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (1)

Fmoc-Leu Alko resin (1.0 g, Leu: 0.80 mmol g⁻¹) was treated with piperidine (20%) in NMP (1×5 min, 1×10min, 1×15 min). After washing the resin with NMP (3×2 min), an HSC(CH₃)₂CH₂COOBt solution, which was prepared by one-hour reaction of HSC(CH₃)₂CH₂COOH (0.19 g, 1.6 mmol), HOBt hydrate (0.28 g, 1.8 mmol) and DCC (0.33g, 1.6 mmol)

in NMP (3.4 mL), was added to the resin. The resulting suspension was mixed for 3h and then washed with NMP (5×2 min). To the resin, an Fmoc-Ala-OBt solution, which was prepared by one hour reaction of Fmoc-Ala (530 mg, 1.6 mmol), HOBt hydrate (0.28 g, 1.8 mmol) and DCC (0.33 g, 1.6 mmol) in NMP (3.4 mL), was added in the presence of DIEA (0.56 ml, 3.2 mmol). The resulting suspension was mixed for 3 h and then washed with NMP (5×2 min). The resin was treated with an NMP solution (10 mL) containing acetic anhydride (1 mL, 9.5 mmol) and DIEA (0.5 mL, 3.0 mmol) for 10 min, and then successively washed with NMP (5×2 min) and MeOH (3×1 min), followed by drying under reduced pressure to give a resin, Fmoc-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (Ala: 0.47 mmol g⁻¹, 1.2 g).

Synthesis of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SC(CH₃)₂CH₂CO-Leu (2) using Fmoc-amino acid derivatives

All peptide chain elongation cycles were carried out manually, as follows: The deprotection of Fmoc groups was carried out by treatment with a reagent, containing 1-methylpyrrolidine (25 mL), HOBt (4.8 g), hexamethylenimine (2 mL) in 100 mL of NMP-DMSO (1:1) solution, (reagent A), (1×3 min, 1×5 min, 1×7 min). The resin was washed with NMP (2×30 sec) and then with an NMP solution containing HOBt (5%, wt/v) (3×30 sec). To the resin, a solution containing the Fmoc-amino acid (4 eq.), HBTU (4.8 eq.), and HOBt (4.8 eq.) in a DMF solution was added. After the addition of DIEA (8 eq.) in NMP, the resulting suspension was mixed for 30 min and then washed with NMP (5×30 sec).

Starting from the Fmoc-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**1**) (95 mg, Ala: 45 μmol), 142 mg of a peptide resin corresponding to the sequence of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13), Boc-Met-Ser(PO(OBzl)OH)-Asp(OBu^t)-Asn(Trt)-Asp(OBu^t)-Asp(OBu^t)-Ile-Glu(OBu^t)-Val-Glu(OBu^t)-Ser(PO(OBzl)OH)-Asp(OBu^t)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin was obtained. An aliquot of this fully protected peptide resin (23 mg) was treated with a reagent (1 ml), composed of EDT (25 μL), water (25 μL), and TFA (0.95 mL), for 2 h. The reaction mixture was added to cold ether (20 mL). The resulting precipitate was washed with ether and collected by centrifugation. The precipitate was washed twice with ether and then dissolved in aqueous acetonitrile. The peptide solution was passed through a dispos-

able ODS cartridge and the product isolated by RP-HPLC. The fraction that contained the product was freeze-dried to give [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SC(CH₃)₂CH₂CO-Leu (**2**) (2.1 mg, 14 % based on Ala in the starting resin): Found: 1830.7 (M+H)⁺ (average). Calcd for (M+H)⁺, 1829.7 (average). Amino acid analysis: Asp_{4,1}Ser_{1,3}Glu_{1,9}Ala₁Val_{0,85}Met_{1,0}Ile_{0,87}Leu_{0,90}.

Preparation of Fmoc(2-F)-amino acids

Fmoc(2-F)-OSu was derived from 2-fluorofluorene, using methods described in the literatures [11, 12]. To an aqueous solution containing an amino acid (2 mmol) and Na₂CO₃ (324 mg, 4 mmol) in water (20 mL) was added a solution of Fmoc(2-F)-OSu (710 mg, 2 mmol) in THF (20 mL). The reaction mixture was stirred for 30 min at room temperature, and then acidified with 5% aqueous citric acid solution. The product was extracted with three portions of ethyl acetate (30 mL). The combined organic layer was washed with 30 mL of saturated NaCl solution and 30 mL of water, followed by drying over Na₂SO₄. After the separation of the desiccant by filtration, the filtrate was concentrated under reduced pressure. The resulting solid or residual oil was crystallized from ethyl acetate/hexane/ether. The melting points of the amino acid derivatives used for this synthesis are as follows: Fmoc(2-F)-Ala (103-4 °C), Fmoc(2-F)-Val (163-5°C), Fmoc(2-F)-Leu (158-160°C), Fmoc(2-F)-Ile (160-2°C), Fmoc(2-F)-Ser(Bu^t) (138-140°C), Fmoc(2-F)-Asp(OBu^t) (124-5°C), Fmoc(2-F)-Glu(OBu^t) (51-54°C), Fmoc(2-F)-Ser(PO(OBzl)OH) (148-9°C).

Preparation of

Fmoc(2-F)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**3**)

To the HSC(CH₃)₂CH₂CO-Leu-Alko resin that was prepared from Fmoc-Leu Alko resin (Leu: 0.80 mmol g⁻¹, 1.0 g) using the same procedure as used for the preparation of resin **1**, an Fmoc(2-F)-Ala-OBt solution, which was prepared by one hour reaction of Fmoc(2-F)-Ala (640 mg, 1.6 mmol), HOBT hydrate (0.28 g, 1.8 mmol), and DCC (0.33 g, 1.6 mmol) in NMP (3.4 mL), was added in the presence of DIEA (0.56 mL, 3.2 mmol). The resulting suspension was mixed for 1 h and then washed with NMP (5×2 min). The resin was treated with an NMP solution (10 mL) containing acetic anhydride (1 mL, 9.5 mmol) and DIEA (0.5 mL, 3.0 mmol) for 10 min and then successively washed with NMP (5×2 min) and MeOH (3×1 min), followed by drying under reduced pressure

to obtain the resin, Fmoc(2-F)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**3**) (Ala: 0.28 mmol g⁻¹, 1.1 g).

Synthesis of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SC(CH₃)₂CH₂CO-Leu (**4**) using Fmoc(2-F)-amino acid derivatives



Peptide chain elongation cycles were carried out manually as described for the synthesis of peptide thioester **2** except for the deblocking time used for the Fmoc(2-F) groups. Deprotection of the Fmoc(2-F) groups was carried out by treatment with reagent A (2×1 min, 1×2 min). Starting from the Fmoc(2-F)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**3**) (32 mg, Ala; 9.0 μmol), 45.9 mg of a peptide resin corresponding to the sequence of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13), Boc-Met-Ser(PO(OBzl)OH)-Asp(OBu^t)-Asn(Trt)-Asp(OBu^t)-Asp(OBu^t)-Ile-Glu(OBu^t)-Val-Glu(OBu^t)-Ser(PO(OBzl)OH)-Asp(OBu^t)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin was obtained. After post-treatment of the resin (15.1 mg) using the same cleavage method as above, followed by RP-HPLC purification, product **4** (2.0 mg) was obtained in 20% yield based on the Ala content of the starting resin: Found: 1830.3 (M+H)⁺ (average). Calcd for (M+H)⁺, 1829.7 (average). Amino acid analysis: Asp_{4,4}Ser_{1,5}Glu_{1,9}Ala₁Val_{0,79}Met_{1,2}Ile_{0,83}Leu_{0,99}.

Results and discussion

The α-thioester of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13) was used as a model since this peptide thioester contains two Ser(PO₃H₂) and four Asp residues. This represents an ideal model compound for use in estimating the utility of the methods developed. The outline of the synthetic route that we examined is summarized in Scheme 1.

Preparation of starting resins

The S-tertiary alkyl thioester type linker was used to suppress the undesirable cyclization of the growing peptides [13]. Fmoc-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**1**) was prepared by a stepwise method. HSC(CH₃)₂CH₂COOH was introduced to the Leu-Alko resin (Leu: 0.80 mmol g⁻¹) in the presence of HOBT hydrate and DCC without added DIEA. To the resin, an Fmoc-Ala-OBt solution was added in the presence of DIEA. The resulting suspension was mixed for 3 h and then treated with an NMP solution



Scheme 1. The synthetic route of phosphorylated peptide thioester by using Fmoc- or Fmoc(2-F) amino acids.

containing acetic anhydride and DIEA to give Fmoc-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin **1** (Ala: 0.47 mmol g⁻¹). Judging from the amino acid analysis, the percentage of Ala introduced to Leu was 70%.

An Fmoc(2-F)-Ala-SC(CH₃)₂CH₂CO-Leu-Alko resin (**3**) was prepared using the same procedure as used for the preparation of resin **1** except for the introduction time used for the Fmoc(2-F)-Ala. The time was shortened to 1 h in order to avoid the undesirable cleavage of Fmoc(2-F) groups by DIEA. Resin **3**, whose substitution by Ala to Leu was 39%, was obtained.

*Syntheses of the α -thioesters of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13) (**2**) using Fmoc-amino acids*

The α -thioester of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13), Met-Ser(PO₃H₂)-Asp-Asn-Asp-Asp-Ile-Glu-Val-Glu-Ser(PO₃H₂)-Asp-Ala-SC(CH₃)₂CH₂CO-Leu (**2**) was prepared using Fmoc-amino acid derivatives and a deblocking reagent (reagent A) that contained 1-methylpyrrolidine, HOBT and hexamethylenimine in the solution of NMP-DMSO (1:1, v/v), which was slightly modified from the original composition [14]. The desired product **2** (peak **a**) was obtained in 14.4% yield after RP-HPLC purification as shown in Fig. 1. This synthesis, however, accompanied a product (peak **b**), whose C-terminal Ala residue was epimerized, in 5.3% yield.




Figure 1. RP-HPLC elution profile of a crude preparation of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SC(CH₃)₂CH₂CO-Leu (**2**) prepared by N^α-Fmoc protection. The product was analyzed using a linear gradient of acetonitrile concentration using a Cosmosil 5C18AR II column (4.6 × 250 mm) at a flow rate of 1.0 ml/min. Peaks **a** and **b** indicate the desired product and the epimerized product, respectively.

*Syntheses of the α-thioesters of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13) (**4**) using Fmoc(2-F)-amino acids*

Fmoc(2-F)-amino acid derivatives were obtained without any problems via the use of Fmoc(2-F)-OSu. Using these Fmoc(2-F)-amino acids, the α-thioester of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13) (**4**) was prepared using the same procedure as was used in the synthesis of peptide thioester **2** except for the time for reagent A treatment. The deblocking of Fmoc(2-F) groups was performed by two 1-min and one 2-min treatments with the reagent A. In this synthesis, the desired product **4** (peak c) was obtained in 20% yield and the epimer (peak d), containing D-Ala, in 2.0% yield as shown in Fig. 2.

Comparison of synthetic methods for the α-thioesters of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)

The α-thioester of [Ser(PO₃H₂)^{2,11}]-p21Max(1-13) was prepared under three different sets of conditions. The first synthesis was carried out by a Boc solid phase method using Boc-Ser[PO₃(cPen)₂] [15] for the introduction of Ser(PO₃H₂) residues. The [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SCH₂CH₂CO-Leu was obtained in 11% yield (peak e in Fig. 3) from Boc-Met-Ser[PO₃(cPen)₂]-Asp(OBzl)-Asn-Asp(OBzl)-Asp(OBzl)-Ile-Glu(OBzl)-Val-Glu(OBzl)-Ser[PO₃(cPen)₂]-Asp(OBzl)-Ala-SCH₂CH₂CO-Leu-OCH₂-Pam resin after TFMSA treatment at 0 °C for 3 h, followed by HPLC purification [16]. In this preparation, the RP-HPLC-purified sample still contained a dehydrated peptide that was separated after the introduction of a Boc group to the terminal amino group. Thus the actual yield of




Figure 2. RP-HPLC elution profile of a crude preparation of [Ser(PO₃H₂)^{2,11}]-p21Max (1-13)-SC(CH₃)₂CH₂CO-Leu (4) prepared by N^α-Fmoc(2-F) protection. The product was analyzed using a linear gradient of acetonitrile concentration using a Cosmosil 5C18AR II column (4.6 × 250 mm) at a flow rate of 1.0 ml/min. Peaks c and d indicate the desired product and the epimerized product, respectively.

the desired product, [Ser(PO₃H₂)^{2,11}]-p21Max(1-13)-SCH₂CH₂CO-Leu, was estimated to be in the vicinity of 9%. Judging from the mass number of peak f, the benzyl group was not completely removed. Peak g indicates the mass number of the 1,2-ethanedithiol adduct, the predicted product of peptide bond cleavage at the N-terminal side of the Ser(PO₃H₂) residue at the second amino acid residue [17]. No epimer peak was detectable by RP-HPLC.

Since phosphopeptides are generally prepared by an Fmoc solid phase method in better yields than by the Boc solid phase method, we applied the Fmoc solid phase method, in which a modified deblocking reagent [14] and Fmoc-Ser(PO(OBzl)OH) [15] are used for the preparation of phosphopeptide thioesters. As expected, the desired product was prepared in higher yield by the Fmoc solid phase method than by the Boc solid phase method. The by-product derived from the phosphorylated amino acid was not observed and the

HOBt in the reagent A appeared to suppress succinimide formation of the Asp(OBu') residues during the removal of the Fmoc groups [18, 19]. One problem that arose in this preparation was the epimerization of the Ala residue adjacent to the thioester. Although the epimer could be easily separated by RP-HPLC in this synthesis, the overall synthesis would be simpler if this side reaction were to be suppressed. The other problem was the relatively low yield of peptide thioester. The major loss of peptide from a resin during chain elongation cycles occurs during deprotection of Fmoc- or Fmoc(2-F)-group on the first and second amino acid residues from the thioester terminal. Usually 70 to 80% of peptide is removed during this process. However, no significant peptide loss was observed after the introduction of the third amino acid residue. The weight increase of a protected peptide resin well agreed with an isolated peptide yield and its RP-HPLC elution profile of a crude product.




Figure 3. Analytical HPLC elution profile of a crude preparation of [Ser(PO₃H₂)^{2,11}]-p21Max (1-13)-SCH₂CH₂CO-Leu prepared by the Boc solid phase method [16]. Peptides were analyzed by linear gradient of acetonitrile concentration using a Cosmosil 5C18AR II column (4.6 × 250 mm) at a flow rate of 1.0 ml/min. Peak e indicates the desired product. Peak f contained a product with a higher mass number than the desired product by 90 and peak g was estimated to be a 1,2-ethanedithiol adduct from its mass number.

As a result, we examined the use of an Fmoc(2-F) group, which would be expected to be a more base-sensitive protecting group than an Fmoc group [20], as an α -amino protecting group. The Fmoc(2-F) groups in the peptide thioester resin could be removed within 4 min by treatment with reagent A. Thus, peptide thioester **4** was obtained in 20% yield, suppressing the generation of the epimer to a 2.0% yield.

Conclusion

A peptide thioester can be prepared by the Fmoc-based solid phase method by using reagent A that contains 1-methylpyrrolidine, HOBt, hexamethylenimine in an NMP-DMSO solution. This reagent enables the deprotection of Fmoc groups while keeping the thioester largely intact. The HOBt in the reagent A suppresses succinimide formation with respect to Asp(OBu^t) residues. This constitutes one of the useful features of reagent A for the preparation of phosphopeptide thioesters, since phosphorylated amino acid residues are often surrounded by Asp residues. No side reaction

derived from Ser(PO(OBzl)OH) was observed in the Fmoc-based preparation.

Acknowledgements

This research was supported, in part by Grants-in-Aid for Scientific Research Nos. 10179101 and 12780440 from the Ministry of Education, Science, Sports and Culture, Japan.

References

1. Hojo, H. and Aimoto, S. *Bull. Chem. Soc. Jpn.*, 64 (1991) 111.
2. Hojo, H., Yoshimura, S., Go, M. and Aimoto, S., *Bull. Chem. Soc. Jpn.*, 68 (1995) 330.
3. Kawakami, T. and Aimoto, S. *Chem. Lett.*, 1997 (1997) 1157.
4. Mizuno, M., Haneda, K., Iguchi, R., Muramoto, I., Kawakami, T., Aimoto, S., Yamamoto, K. and Inazu, T., *J. Am. Chem. Soc.*, 121 (1999) 284.
5. Aimoto, S., *Biopolymers (Pep. Sci.)*, 51 (1999) 247.
6. Kawakami, T., Hasegawa, K. and Aimoto, S., *Bull. Chem. Soc. Jpn.*, 73 (2000) 197.
7. Dawson, P. E., Muir, T. W., Clark-Lewis, I., Kent, S. B., *Science*, 266 (1994) 776.

8. Tam, J. A., Yu, Q. and Miao, Z., *Biopolymer (Pept. Sci.)*, 51 (1999) 311.
9. Bodanszky, M., Tolle, J. C., Deshmane, S. S. and Bodanszky, A., *Int. J. Peptide Protein Res.*, 12, (1978) 57–68
10. Bodanszky, M. and Kwei, J. Z., *Int. J. Peptide Protein Res.*, 12, (1978) 69–74.
11. a. Carpino, L.A. and Han, G.Y., *J. Org. Chem.*, 37 (1972) 3404.
b. Carpino, L.A. and Han, G.Y., *J. Org. Chem.*, 38 (1973) 4218.
12. Ten Kortenaar, P. B. W., Van Dijk, B. G., Peeters, J. M., Raaben, B. J., Adams, P. J. H. and Tesser, G., *Int. J. Peptide Protein Res.*, 27 (1986) 398.
13. Hojo, H., Kwon, Y., Kakuta, Y., Tsuda, S., Tanaka, I., Hikichi, K. and Aimoto, S., *Bull. Chem. Soc. Jpn.*, 66 (1993) 2700.
14. Li, X., Kawakami, T. and Aimoto, S. *Tetrahedron Lett.*, 39 (1998) 8669.
15. Wakamiya, T., Togashi, R., Nishida, T., Saruta, K., Yasuoka, J., Kusumoto, S., Aimoto, S., Kumagaye, K. Y., Nakajima, K. and Nagata, K., *Bioorg. Med. Chem.*, 5 (1997) 135.
16. Kawakami, T., Hasegawa, K., Teruya, K., Akaji, K., Horiuchi, M., Inagaki, F., Kurihara, Y., Uesugi, S. and Aimoto, S., *J. Peptide Science*, 7 (2001) 474.
17. Kawakami, T., Hasegawa, K. and Aimoto, S., *Bull. Chem. Soc. Jpn.*, 73 (2000) 197.
18. Martinez, J. and Bodanszky, M. *Int. J. Pept. Protein Res.*, 12 (1978) 277.
19. Lauer, J. L., Fields, C. G. and Fields, G. B., *Lett. Pept. Sci.*, 1 (1995) 197.
20. Bordwell, F. G. and McCollum, G. J., *J. Org. Chem.*, 41 (1976) 2391.